Trial Profile

Pilot Study to Evaluate 64Cu-DOTA-Trastuzumab Imaging in Patients With HER2+ Breast Cancer With Brain Metastatsis Treated With Fam-Trastuzumab Deruxtecan

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab (Primary) ; Trastuzumab-deruxtecan (Primary)
Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
Focus Diagnostic use

Most Recent Events

15 Feb 2024 Planned End Date changed from 25 Feb 2025 to 25 Feb 2026.
15 Feb 2024 Planned primary completion date changed from 25 Feb 2025 to 25 Feb 2026.
09 Dec 2023 Trial design, presented at the 46th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com